Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar 4;20(1):69.
doi: 10.1186/s12957-021-02451-8.

The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis

Anan Gong  1 , Xiaofei Li  2
Affiliations
Meta-Analysis

The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis

Anan Gong et al. World J Surg Oncol. .

Abstract

Background: The timely and effective treatments are vital to the prognosis of patients with hepatocellular carcinoma, and the role of Apatinib combined with TACE in the treatment of hepatocellular carcinoma remains unclear. Therefore, we aimed to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of Apatinib combined with transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma.

Methods: We searched for randomized controlled trials (RCTs) on Apatinib and TACE use in the treatment of hepatocellular carcinoma. Cochrane Central Register of Controlled Trials, Embase, PubMed, China Biomedical Literature Database, China Knowledge Network, Wanfang Database, and Weipu Chinese Science and Technology Journal Database were searched up to 16 April 2021. Two researchers independently screened the literature and extracted data according to the inclusion and exclusion criteria. RevMan 5.3 software was used for Meta-analysis. This meta-analysis protocol had been registered online (available at: https://inplasy.com/inplasy-2021-6-0047/ ).

Results: A total of 14 RCTs involving 936 hepatocellular carcinoma patients were included. The objective remission rate (OR = 2.93, 95% CI 2.17-3.95), 1-year survival (OR = 2.47, 95% CI 1.65-3.68), 2-year survival (OR = 2.67, 95% CI 1.41-5.04), the incidence of hand-foot syndrome (OR = 32.09, 95% CI 10.87-94.74) and the incidence of proteinuria (OR = 14.79, 95% CI 6.07-36.06) of the Apatinib + TACE group was significantly higher than that of the TACE group (all P < 0.05). There were no significant differences in the incidence of myelosuppression (OR = 1.01, 95% CI 0.61-1.67), the incidence of hypertension (OR = 7.56, 95% CI 0.95-1.67, P = 60.17) between Apatinib + TACE and TACE group (all P > 0.05).

Conclusions: Apatinib combined with TACE is more effective than TACE alone in the treatment of hepatocellular carcinoma, but it has certain adverse reactions.

Keywords: Apatinib; Cancer; Effect; Liver; Review; Safety; TACE; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram for study selection
Fig. 2
Fig. 2
Risk of bias graph
Fig. 3
Fig. 3
Risk of bias summary
Fig. 4
Fig. 4
The forest plots for synthesized outcomes
Fig. 5
Fig. 5
The forest plots for synthesized outcomes
Fig. 6
Fig. 6
Funnel plot for the objective remission rates
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kim YJ, Jang H, Lee K, Park S, Min SG, Hong C, et al. PAIP 2019: liver cancer segmentation challenge. Med Image Anal. 2021;67:101854. - PubMed
    1. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394(10204):1145–1158. - PMC - PubMed
    1. Global Burden of Disease Liver Cancer C. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National Level: results from the global burden of disease study. JAMA Oncol 2017. 2015;3(12):1683–1691. - PMC - PubMed
    1. Sakuraoka Y, Kubota K, Tanaka G, Shimizu T, Tago K, Park KH, et al. Is left-sided involvement of hepatocellular carcinoma an important preoperative predictive factor of poor outcome? World J Surg Oncol. 2020;18(1):317. - PMC - PubMed
    1. Pan R, Zhu M, Yu C, Lv J, Guo Y, Bian Z, et al. Cancer incidence and mortality: a cohort study in China, 2008-2013. Int J Cancer. 2017;141(7):1315–1323. - PubMed